) Total liabilities 993.33 988.16 5.17 0.52 Equity Share Capital - Authorized 140.00 140.00 - - Issued and paid-up 140.00 100.00 40.00 40.00 Share premium 246.11 - 246.11 n/a Retained earning Appropriated
- - Issued and paid-up 140.00 140.00 - - Share premium 246.11 246.11 - - Retained earning - Appropriated - legal reserve 9.15 9.15 - - Unappropriated 90.86 87.31 3.55 4.07 Equity attributable to owners of the
Appropriated - legal reserve 0.92 1.56 3.00 Unappropriated 20.31 49.28 66.94 Total shareholders' equity 30.23 59.84 466.94 Total liabilities and shareholders' equity 170.81 190.45 697.62 Operation Results of
Appropriated - legal reserve 0.92 1.56 3.00 Unappropriated 20.31 49.28 66.94 Total shareholders' equity 30.23 59.84 466.94 Total liabilities and shareholders' equity 170.81 190.45 697.62 Operation Results of
988.16 (98.80) (10.00) Equity Share Capital - Authorized 140.00 140.00 - - Issued and paid-up 140.00 100.00 40.00 40.00 Share premium 246.11 - 246.11 n.a. Retained earning Appropriated - legal reserve 5.09
- - Retained earnings - Appropriated - Legal reserve 45.2 45.2 - - Retained earnings - Unappropriated 4,631.7 4,309.0 322.7 7.5 Deficit from business combination (22.9) (22.9) - - Non-controlling interests 56.6
clarify or submit additional documents evidence as appropriated within specified period. If such person fails to comply or proceed as required, the Office shall deem that such person does not intend to
qualified to be property fund manager applying for renewal to clarify or submit additional documents evidence as appropriated within specified period. If such person fails to comply or proceed as required
qualified to be property fund manager applying for renewal to clarify or submit additional documents evidence as appropriated within specified period. If such person fails to comply or proceed as required
increased by 92. 0 MB, representing an increase of 5. 6% because the operating profit for the Q1-2023 subtracted to the retained earnings appropriated as legal reserve. Sincerely yours, (Ms. Sarin